ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1061

Utilization of Electronic Health Record System to Improve Glucocorticoid Induced Osteoporosis Screening and Treatment

Anupama Shahane1, Marissa Blum2, Andrew Kanoff3, Kristel Frey4, Sean Looby5 and Nora Sandorfi1, 1University of Pennsylvania, Philadelphia, PA, 2Temple University Health System, Philadelphia PA, Philadelphia, 3University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, 4University of Pennsylvania, Philadelphia PA, Philadelphia, PA, 5University of Pennsylvania, Philadelphia PA, Philadelphia

Meeting: ACR Convergence 2024

Keywords: osteoporosis, quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Osteoporosis is the most common bone disease leading to fragility fractures associated with significant morbidity and increased mortality (1). Glucocorticoids (GC) are widely used medications and are an important risk factor for bone loss. Fracture risk is increased with both high and chronic low dose GC therapy with highest rate of bone loss within 3-6 months of starting therapy. The American College of Rheumatology (ACR) has published glucocorticoid induced osteoporosis (GIOP) prevention guidelines to reduce fractures associated with GC therapy (2). Despite availability of guidelines and effective anti-fracture therapy, not all patients on GCs are screened or treated for GIOP. We report on the implementation of an intervention to improve bone health screening in patients on high dose or long-term GC therapy utilizing the electronic health record (EHR) system.

Methods: Within the Division of Rheumatology, patients were identified based on glucocorticoid prescriptions. Among patients receiving long term or high dose GCs, 100 charts were screened for dual Xray absorptiometry (DXA) ordered and reviewed within past 2 years, prescription of anti-osteoporosis medication, and documentation of bone health plan in office notes.

We created an EHR based intervention – best practice alert (BPA) that triggers based on prednisone prescriptions identifying patients >50 years of age receiving prednisone prescriptions of ³10 mg daily as a 90-day supply or with ³ 2 refills. The BPA allows providers to choose to address bone health during the alert, defer to another time, or provide a reason to not address currently. The BPA also provides information on date of last EHR captured DXA results and osteoporosis specific medications. Providers received education regarding GIOP prevention and the purpose of the BPA. Regular performance review was conducted and feedback was provided. Two years after executing the BPA in the EHR, qualifying charts were reviewed to measure change in practice.

Results: Baseline data identified that 35% of patients on glucocorticoids did not have bone health addressed at initiation or during the first 6 months of therapy, as recommended in the GIOP screening guidelines. Follow up data over 2 years showed a sustained increase in the proportion of patients receiving bone health screening from 65.8% to 88.5% in the division. On polling providers, 73% of providers found the BPA helpful and preferred to continue getting the BPA as a monthly reminder.

Conclusion: GIOP screening is critical in patients on high dose and/ or chronic GC therapy. Patients on glucocorticoids are often under screened for bone health despite available recommendations for several reasons, including visit time and complexity. Our goal to improve bone health screening was accomplished using a BPA designed to prompt providers to address bone health for patients on high dose and/or chronic GC therapy. EHR systems can be utilized as a best practice method to improve bone health screening in patients on chronic GC, in turn increasing early identification and treatment of osteoporosis and prevention of fractures.  

Supporting image 1

% of patients with bone health currently addressed

Supporting image 2

Provider Survey


Disclosures: A. Shahane: None; M. Blum: None; A. Kanoff: None; K. Frey: None; S. Looby: None; N. Sandorfi: Bristol-Myers Squibb(BMS), 2, Novartis, 1.

To cite this abstract in AMA style:

Shahane A, Blum M, Kanoff A, Frey K, Looby S, Sandorfi N. Utilization of Electronic Health Record System to Improve Glucocorticoid Induced Osteoporosis Screening and Treatment [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/utilization-of-electronic-health-record-system-to-improve-glucocorticoid-induced-osteoporosis-screening-and-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utilization-of-electronic-health-record-system-to-improve-glucocorticoid-induced-osteoporosis-screening-and-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology